Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xtandi’s Success A Double-Edged Sword

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas/Medivation prostate cancer drug is the latest focus of drug pricing criticism in the news but it doesn’t seem likely that NIH will grant open licenses on the drug’s patent under its “march-in” authority, as legislators and advocacy groups request.

You may also be interested in...



NIH Resists “March In” On Norvir Patents Based On Pricing Concerns

NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.

Payer Transparency Reforms: Moving From Rebates To Drug Access Restrictions

Institute for Clinical and Economic Review analysis of whether payers are providing “fair access” to fairly priced drugs was hampered by a lack of transparency among payers, leading to calls for reform.

Step Therapy: As Bill Aims To Routinize Processes, Study Finds Policies Often Stricter Than Clinical Guidelines

Chronic migraine and anti-inflammatory treatments were most often subject to step therapy, Tufts researchers found. Policies varied from payer to payer, raising concerns over the impact of shifting requirements for treating the same disease as patients move among insurers.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel